Mamata Gokhale

Mamata is passionate about drug development, with extensive experience in oncology, hematology and cardiovascular areas. Her track record of obtaining regulatory designations and facilitating FDA/EMA interactions demonstrates commitment to advancing healthcare.

Mamata’s journey in the field of Global Regulatory Affairs and Clinical Development started in academia at Johns Hopkins followed by a reviewer role at the FDA and then nearly 25 years in the industry that included leadership roles in small, mid-sized, and large pharmaceutical and biotech companies.

Her educational background includes a Masters and Ph.D. in Biochemistry from the University of Bombay, India, as well as post-doctoral training at the renowned John Hopkins School of Medicine & Public Health. She also holds RAC certification from the Regulatory Affairs Professionals Society. Throughout her career, she has demonstrated expertise in the development of small molecules, monoclonal antibodies, cell and gene therapies, and in the niche upcoming area of theranostic radiopharmaceuticals. Her experience in navigating complex regulatory environments and her ability to bridge clinical strategy with regulatory requirements has proven to be highly valuable.

Mamata’s most recent role as the Vice President of Global Regulatory Affairs at Perspective Therapeutics was focused on the dose optimization strategy for a peptide and radioisotope conjugate targeting neuroendocrine tumors and getting accepted in FDA’s CDRP program to ensure alignment between clinical development and chemistry/manufacturing controls. Prior to that, a similar role at Sierra Oncology culminated in the successful submission of an NDA and approval for myelofibrosis. Her contribution to this achievement was pivotal, as it led to the acquisition of Sierra Oncology by GSK in 2022.